BACKGROUNDAlzheimer's (AD) is a debilitating disease characterized by a loss of memory and executive function. A growing number of studies have shown a direct correlation between hypertension and increased risk of AD-like symptoms, including cognitive deficits, increased Aβ production and neuronal death. Furthermore, Renin-Angiotensin System (RAS) targeted anti-hypertensives reduce risk. This has prompted studies demonstrating that the protective arm of RAS, via activation of the MAS receptor, is reduced in AD patients, suggesting MAS agonists may protect against ROS production and exotoxicity while also increasing cognition and being cardioprotective. We hypothesize that MAS agonists can ameliorate AD-like pathology in mice using a model of heart failure - transverse aortic constriction (TAC).METHODOne week after TAC surgery, C57Bl/6J male mice (8-10wk) started treatment with saline or one of four Mas agonists. Four weeks after surgery, cardiac function was assessed by echocardiography followed by cognitive assessment (10 weeks) using novel object recognition. At 90days, brain, heart and blood were collected and analyzed for phenotypic and functional changes.RESULTTAC surgery induced marked morphological changes in cardiac tissue (cardiomyocyte area, fibrosis and apoptosis). The subsequent dysfunction manifested as decreases in standard cardiac measures of left ventricular function and by extension - cognition, which were rescued by MAS agonists. This treatment effect is partly due to a protection of the mitochondrial oxidative phosphorylation pathway rather than biogenesis. Specifically, marked ROS-induced mitochondrial dysfunction occurring within neurons and microglia were reduced with MAS agonist treatment. Further Seahorse analysis revealed a resistance to TAC-induced reductions in mitochondrial complex activity. This trend extended to the heart, improving outcomes for endothelial cells and cardiomyocytes.CONCLUSIONThe Mas agonist RASRx1902 significantly decreased several measures of AD-like pathology in the TAC model with particular focus on cardioprotection and mitochondrial function, indicating that it may be beneficial in those with hypertension as a risk factor for AD development. Future work will focus on further characterizing RASRx1902 effects in affected cellular pathway changes, efficacy in a pilot study examining cerebral blood flow, blood brain barrier integrity, and effects on neuronal function.

100 Deals associated with MMX-1902

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Preclinical	US	University of Arizona	-
Muscular Dystrophy, Duchenne	Preclinical	US	University of Arizona	-
Muscular Dystrophy, Duchenne	Preclinical	US	RASRx LLC	-
Motor Neuron Disease	Discovery	US	RASRx LLC	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

MMX-1902

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation